|
1
|
Sherrard DJ, Hercz G, Pei Y, Maloney NA,
Greenwood C, Manuel A, Saiphoo C, Fenton SS and Segre GV: The
spectrum of bone disease in end stage renal failure-an evolving
disorder. Kidney Int. 43:436–442. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Afifi A: Renal osteodystrophy in
developing countries. Artif Organs. 26:767–769. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mathias R, Salusky I, Harman W, Paredes A,
Emans J, Segre G and Goodman W: Renal bone disease in pediatric and
young adult patients on hemodialysis in a children’s hospital. J Am
Soc Nephrol. 3:1938–1946. 1993.PubMed/NCBI
|
|
4
|
Moore C, Yee J, Malluche H, Rao DS,
Monier-Faugere MC, Adams E, Daramola-Ogunwuyi O, Fehmi H, Bhat S
and Osman-Malik Y: Association between bone histology and markers
of bone and mineral metabolism in african-american hemodialysis
patients. Clin J Am Soc Nephrol. 4:1484–1493. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferreira A, Saraiva M, Behets G, Macedo A,
Galvão M, D’Haese P and Drüeke TB: evaluation of bone remodeling in
hemodialysis patients: Serum biochemistry, circulating cytokines
and bone histomorphometry. J Nephrol. 22:783–793. 2009.PubMed/NCBI
|
|
6
|
Bervoets AR, Spasovski GB, Behets GJ, Dams
G, Polenakovic MH, Zafirovska K, Van Hoof VO, De Broe Me and
D’Haese PC: Useful biochemical markers for diagnosing renal
osteodystrophy in predialysis end-stage renal failure patients. Am
J Kidney Dis. 41:997–1007. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Portale AA, Zhang MY, David V, Martin A,
Jiao Y, Gu W and Perwad F: Characterization of FGF23-dependent
egr-1 cistrome in the mouse renal proximal tubule. PLoS One.
10:e01429242015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu P, Xuan Q, Hu B, Lu L, Wang J and Qin
YH: Fibroblast growth factor-23 helps explain the biphasic
cardiovascular effects of vitamin D in chronic kidney disease. Int
J Biol Sci. 8:663–671. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bai X, Miao D, Li J, Goltzman D and
Karaplis AC: Transgenic mice overexpressing human fibroblast growth
factor 23 (R176Q) delineate a putative role for parathyroid hormone
in renal phosphate wasting disorders. endocrinology. 145:5269–5279.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang H, Yoshiko Y, Yamamoto R, Minamizaki
T, Kozai K, Tanne K, Aubin JE and Maeda N: Overexpression of
fibroblast growth factor 23 suppresses osteoblast differentiation
and matrix mineralization in vitro. J Bone Miner Res. 23:939–948.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Parker VJ, Harjes LM, Dembek K, Young GS,
Chew DJ and Toribio RE: Association of Vitamin D metabolites with
parathyroid hormone, fibroblast growth factor-23, calcium, and
phosphorus in dogs with various stages of chronic kidney disease. J
Vet Intern Med. 31:791–798. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Isakova T, Xie H, Yang W, Xie D, Anderson
AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, et al
Chronic renal Insufficiency Cohort (Cric) Study Group: Fibroblast
growth factor 23 and risks of mortality and end-stage renal disease
in patients with chronic kidney disease. JAMA. 305:2432–2439. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim J and Shin W: How to do random
allocation (randomization). Clin Orthop Surg. 6:103–109. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
15
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu P, Qin YH, Pei J, Lei FY, Hu B and Lu
L: Beneficial effect of all-trans retinoic acid (ATRA) on
glomerulosclerosis rats via the downregulation of alpha-smooth
muscle actin: A comparative study between ATRA and benazepril. Exp
Mol Pathol. 89:51–57. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Okuda S, Oh Y, Tsuruda H, Onoyama K,
Fujimi S and Fujishima M: Adriamycin-induced nephropathy as a model
of chronic progressive glomerular disease. Kidney Int. 29:502–510.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Van Vleet JF and Ferrans VJ: Clinical and
pathologic features of chronic adriamycin toxicosis in rabbits. Am
J Vet Res. 41:1462–1469. 1980.PubMed/NCBI
|
|
19
|
Ishii H, Wada M, Furuya Y, Nagano N,
Nemeth EF and Fox J: Daily intermittent decreases in serum levels
of parathyroid hormone have an anabolic-like action on the bones of
uremic rats with low-turnover bone and osteomalacia. Bone.
26:175–182. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu HJ, Yiu WH, Wong DW, Li RX, Chan LY,
Leung JC, Zhang Y, Lian Q, Lai KN, Tse HF, et al: Human induced
pluripotent stem cell-derived mesenchymal stem cells prevent
adriamycin nephropathy in mice. Oncotarget. 8:103640–103656. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Wang YP, Tay YC and Harris DC:
Progressive adriamycin nephropathy in mice: Sequence of histologic
and immunohistochemical events. Kidney Int. 58:1797–1804. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brod J and Sirota JH: The renal clearance
of endogenous ‘creatinine’ in man. J Clin Invest. 27:645–654. 1948.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cousins C, Mohammadtaghi S, Mubashar M,
Strong R, Gunasekera RD, Myers MJ and Peters AM: Clearance kinetics
of solutes used to measure glomerular filtration rate. Nucl Med
Commun. 20:1047–1054. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu P, Huang BY, Xia X, Xuan Q, Hu B and
Qin YH: Therapeutic effect of CNP on renal osteodystrophy by
antagonizing the FGF-23/MAPK pathway. J Recept Signal Transduct
Res. 36:213–219. 2016. View Article : Google Scholar
|
|
25
|
Wolf M: Update on fibroblast growth factor
23 in chronic kidney disease. Kidney Int. 82:737–747. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Doyon A, Fischer DC, Bayazit AK, Canpolat
N, Duzova A, Sözeri B, Bacchetta J, Balat A, Büscher A, Candan C,
et al: Markers of bone metabolism are affected by renal function
and growth hormone therapy in children with chronic kidney disease.
PLoS One. 10:e01134822015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hasegawa H, Nagano N, Urakawa I, Yamazaki
Y, Iijima K, Fujita T, Yamashita T, Fukumoto S and Shimada T:
Direct evidence for a causative role of FGF23 in the abnormal renal
phosphate handling and vitamin D metabolism in rats with
early-stage chronic kidney disease. Kidney Int. 78:975–980. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Urakawa I, Yamazaki Y, Shimada T, Iijima
K, Hasegawa H, Okawa K, Fujita T, Fukumoto S and Yamashita T:
Klotho converts canonical FGF receptor into a specific receptor for
FGF23. Nature. 444:770–774. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mace ML, Gravesen E, Nordholm A,
Hofman-Bang J, Secher T, Olgaard K and Lewin E: Kidney fibroblast
growth factor 23 does not contribute to elevation of its
circulating levels in uremia. Kidney Int. 92:165–178. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shalhoub V, Ward SC, Sun B, Stevens J,
Renshaw L, Hawkins N and Richards WG: Fibroblast growth factor 23
(FGF23) and alpha-klotho stimulate osteoblastic MC3T3e1 cell
proliferation and inhibit mineralization. Calcif Tissue Int.
89:140–150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schmid TM and Linsenmayer TF:
Immunohistochemical localization of short chain cartilage collagen
(type X) in avian tissues. J Cell Biol. 100:598–605. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kwan AP, Cummings CE, Chapman JA and Grant
ME: Macromolecular organization of chicken type X collagen in
vitro. J Cell Biol. 114:597–604. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chung KS, Jacenko O, Boyle P, Olsen BR and
Nishimura I: Craniofacial abnormalities in mice carrying a dominant
interference mutation in type X collagen. Dev Dyn. 208:544–552.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chan D, Weng YM, Graham HK, Sillence DO
and Bateman JF: A nonsense mutation in the carboxyl-terminal domain
of type X collagen causes haploinsufficiency in schmid metaphyseal
chon-drodysplasia. J Clin Invest. 101:1490–1499. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang X, Wang S, Li C, Gao T, Liu Y,
Rangiani A, Sun Y, Hao J, George A, Lu Y, et al: Inactivation of a
novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in
mice. PLoS Genet. 8:e10027082012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu ES, Martins JS, Raimann A, Chae BT,
Brooks DJ, Jorgetti V, Bouxsein ML and Demay MB:
1,25-Dihydroxyvitamin D alone improves skeletal growth,
microarchitecture, and strength in a murine model of XLH, despite
enhanced FGF23 expression. J Bone Miner Res. 31:929–939. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kanda E, Yoshida M and Sasaki S:
Applicability of fibroblast growth factor 23 for evaluation of risk
of vertebral fracture and chronic kidney disease-mineral bone
disease in elderly chronic kidney disease patients. BMC Nephrol.
13:1222012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Riminucci M, Collins MT, Fedarko NS,
Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T,
Econs MJ, et al: FGF-23 in fibrous dysplasia of bone and its
association to renal phosphate wasting. Clin J Invest. 112:683–692.
2003. View Article : Google Scholar
|
